Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials

被引:108
作者
Kent, David M. [1 ]
Nelson, Jason [1 ]
Dahabreh, Issa J. [1 ,2 ,3 ,4 ]
Rothwell, Peter M. [5 ]
Altman, Douglas G. [6 ]
Hayward, Rodney A. [7 ,8 ]
机构
[1] Tufts Univ, Sch Med, Tufts Med Ctr, Predict Analyt & Comparat Effectiveness Ctr, Boston, MA 02111 USA
[2] Brown Univ, Ctr Evidence Based Med, Providence, RI 02912 USA
[3] Brown Univ, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA
[4] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA
[5] Univ Oxford, Nuffield Dept Clin Neurosci, Stroke Prevent Res Unit, Oxford, England
[6] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Ctr Stat Med, Oxford, England
[7] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[8] Univ Michigan, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
Risk prediction; heterogeneity of treatment effect; subgroup analysis; personalized medicine; patient-centered outcomes research; PERCUTANEOUS CORONARY INTERVENTION; MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; BENEFIT; PROGRESSION; STRATEGIES; REDUCTION; MORTALITY; OUTCOMES; SUPPORT;
D O I
10.1093/ije/dyw118
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Risk of the outcome is a mathematical determinant of the absolute treatment benefit of an intervention, yet this can vary substantially within a trial population, complicating the interpretation of trial results. Methods: We developed risk models using Cox or logistic regression on a set of large publicly available randomized controlled trials (RCTs). We evaluated risk heterogeneity using the extreme quartile risk ratio (EQRR, the ratio of outcome rates in the lowest risk quartile to that in the highest) and skewness using the median to mean risk ratio (MMRR, the ratio of risk in the median risk patient to the average). We also examined heterogeneity of treatment effects (HTE) across risk strata. Results: We describe 39 analyses using data from 32 large trials, with event rates across studies ranging from 3% to 63% (median = 15%, 25th-75th percentile = 9-29%). C-statistics of risk models ranged from 0.59 to 0.89 (median = 0.70, 25th-75th percentile = 0.65-0.71). The EQRR ranged from 1.8 to 50.7 (median = 4.3, 25th-75th percentile = 3.0-6.1). The MMRR ranged from 0.4 to 1.0 (median = 0.86, 25th-75th percentile = 0.80-0.92). EQRRs were predictably higher and MMRRs predictably lower as the c-statistic increased or the overall outcome incidence decreased. Among 18 comparisons with a significant overall treatment effect, there was a significant interaction between treatment and baseline risk on the proportional scale in only one. The difference in the absolute risk reduction between extreme risk quartiles ranged from -3.2 to 28.3% (median - 5.1%; 25th-75th percentile = 0.3-10.9). Conclusions: There is typically substantial variation in outcome risk in clinical trials, commonly leading to clinically significant differences in absolute treatment effects. Most patients have outcome risks lower than the trial average reflected in the summary result. Risk-stratified trial analyses are feasible and may be clinically informative, particularly when the outcome is predictable and uncommon.
引用
收藏
页码:2075 / 2088
页数:14
相关论文
共 68 条
[1]  
Alderman EL, 1996, NEW ENGL J MED, V335, P217
[2]   Calculating the number needed to treat for trials where the outcome is time to an event [J].
Altman, DG ;
Andersen, PK .
BRITISH MEDICAL JOURNAL, 1999, 319 (7223) :1492-1495
[3]  
[Anonymous], 1989, NEW ENGL J MED, V320, P618
[4]  
[Anonymous], 1979, JAMA, V242, P2562
[5]  
[Anonymous], GSK CLIN STUD DAT
[6]  
[Anonymous], 2011, Base SAS 9.3 procedures guide
[7]  
[Anonymous], INT J CARDIOL C
[8]  
[Anonymous], XIGR DROTR ALF ACT P
[9]   Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial [J].
Antman, E ;
Cooper, H ;
Domanski, M ;
Feinstein, S ;
Gersh, B ;
Gibler, WB ;
Haigney, M ;
Hochman, J ;
McKinlay, S ;
Norman, J ;
Opie, L ;
Rogers, W ;
Rosenberg, Y ;
Woods, K ;
Mills, P ;
Rosenberg, Y ;
Assmann, S ;
Woods, K ;
Nannicelli, J ;
Scott, J ;
Oakleaf, K ;
Singh, S ;
Davis, B ;
Hallstrom, A ;
Levine, R ;
Robertson, R ;
Norman, J ;
Gretton, V ;
Scott, K ;
Dolan, S ;
Brown, M ;
Ewart, A ;
Hendriks, R ;
Jeffrey, I ;
Newman, R ;
Quinn, W ;
Rankin, J ;
Russell, A ;
Singh, B ;
Waites, J ;
Ziffer, R ;
Smetana, R ;
Col, J ;
Bruno, P ;
Evrard, P ;
Massart, PE ;
Vrabevski, M ;
Andreev, N ;
Benov, H ;
Boichev, B .
LANCET, 2002, 360 (9341) :1189-1196
[10]   The TIMI risk score for unstable angina/non-ST elevation MI - A method for prognostication and therapeutic decision making [J].
Antman, EM ;
Cohen, M ;
Bernink, PJLM ;
McCabe, CH ;
Horacek, T ;
Papuchis, G ;
Mautner, B ;
Corbalan, R ;
Radley, D ;
Braunwald, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (07) :835-842